SRPT

Sarepta Therapeutics, Inc. (SRPT) Presents at RBC Capital Markets Global Healthcare Broker Conference Call - (Transcript)

Sarepta's stock is up 11% on positive data from clinical trial for Duchenne treatment

Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta's Commercial Process Material

Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday

Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Why Sarepta's Q1 Results Won't Spark a Rebound for the Beaten-Down Biotech